Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neutropenia
Interventions: DRUG: SPI-2012|DRUG: Pegfilgrastim|DRUG: Docetaxel|DRUG: Cyclophosphamide
Sponsor: Spectrum Pharmaceuticals, Inc